0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma

Andrew C. Birkeland, MD1; Megan Yanik, BS2; Brittny N. Tillman, MD1; Megan V. Scott, BS2; Susan K. Foltin, BS1; Jacqueline E. Mann, BS1; Nicole L. Michmerhuizen, BS1; Megan L. Ludwig, BS1; Morgan M. Sandelski, BS2; Christine M. Komarck, BS1; Thomas E. Carey, PhD1,3; Mark E. P. Prince, MD1,3; Carol R. Bradford, MD1,3; Jonathan B. McHugh, MD4; Matthew E. Spector, MD1,3; J. Chad Brenner, PhD1,3
[+] Author Affiliations
1Department of Otolaryngology–Head and Neck Surgery, University of Michigan Medical School, Ann Arbor
2medical student, University of Michigan Medical School, Ann Arbor
3Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor
4Department of Pathology, University of Michigan Medical School, Ann Arbor
JAMA Otolaryngol Head Neck Surg. 2016;142(6):559-567. doi:10.1001/jamaoto.2016.0335.
Text Size: A A A
Published online

Importance  ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC.

Objective  To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs.

Design, Setting, and Participants  A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excellence was conducted. Publicly available sequencing data (The Cancer Genome Atlas), as well as data from other studies, were reviewed to identify additional mutations and overexpression in ERBB2 in HNSCC. Established HNSCC cell lines were used for follow-up in vitro analysis. The study was conducted from October 1, 2014, to August 30, 2015.

Interventions  With the use of targeted, amplicon-based sequencing with the Oncomine Cancer Panel, the copy number and mutation status of commonly altered genes in HNSCCs were assessed. Immunohistochemical staining was performed on tissue microarrays of HNSCCs to assess the expression of ERBB2. Western blotting for HNSCC cell line ERBB2 expression and cell survival assays after treatment with ERBB2 inhibitors were performed.

Main Outcomes and Measures  The prevalence of ERBB2 genetic aberrations and ERBB2 overexpression in laryngeal and oral cavity SCCs, prevalence of ERBB2 aberrations in HNSCC in The Cancer Genome Atlas, ERBB2 protein expression in HNSCC cell lines, and response of HNSCC cell lines to targeted ERBB2 inhibitors.

Results  Of the 42 laryngeal SCC samples screened by targeted sequencing, 4 (10%) were positive for ERBB2 amplification. Two of these samples showed ERBB2 overexpression on immunohistochemistry. Two of the 94 oral cavity SCC samples (2%) were positive for ERBB2 on immunohistochemistry. Analysis of 288 patients from publicly available HNSCC sequencing data revealed 9 amplifications (3%) in ERBB2. Protein expression was variable across HNSCC cell lines, and a subset of these cell lines showed responsiveness to anti-ERBB2 therapy.

Conclusions and Relevance  ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Figures

Place holder to copy figure label and caption
Figure 1.
Copy Number Analysis of ERBB2-Positive Laryngeal Cancer Samples

Genes from the comprehensive Oncomine Cancer Panel were assessed for relative copy number by Ion Torrent sequencing. Genes are plotted along the x-axis beginning with chromosome 1 and ending with the X chromosome. Each color represents probe sets for an individual gene, and each point represents an individual probe. Only statistically differential genes are highlighted, with amplified genes in green text and depleted genes in purple text. CN indicates copy number.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
ERBB2 Immunohistochemistry Demonstrates Protein Overexpression in Head and Neck Squamous Cell Carcinoma (SCC)

ERBB2 overexpression is demonstrated in laryngeal SCC (A) and oral cavity SCC (C) samples. Corresponding stains were performed (hematoxylin-eosin, original magnification ×40) (B and D). Representative images of positive cases were used to demonstrate staining.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
ERBB2 Expression in The Cancer Genome Atlas (TCGA) Head and Neck Squamous Cell Carcinoma (HNSCC) Data Sets

ERBB2 amplifications are identified in specific HNSCC samples. A, Using the TCGA data, copy number was plotted along on a log scale such that points (each representing individual patients) to the right of the dotted blue line had statistically significant increases in ERBB2 copy number. RNA overexpression of ERBB2 is also identified in these HNSCC samples. B, Using the TCGA data, we stratified patients by disruptive genomic events in each of the 4 ERBB genes. Color represents the type of genomic aberration as indicated. C, Comparison of RNA expression of ERBB2 and EGFR across breast cancer, cervical SCC, and HNSCC. D, Mutations in ERBB2 and other members of the EGFR family are also identified (B and D), and the distribution of mutations in ERBB2 is shown in the schematic. The line across the middle represents the length of the gene. N indicates N terminus; C, C terminus; and TM, transmembrane domain.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.
ERBB2 Protein Expression in Head and Neck Squamous Cell Carcinoma (SCC) Cell Lines

ERBB2 and EGFR levels across multiple oral cavity SCC (UM-SCC-1, -2, -14A, -23, -49, -59, -92, -97, -103, -108, and -110) and laryngeal SCC (UM-SCC-23) cell lines. Overexpression of ERBB2 was seen in UM-SCC-1 in comparison with the remaining cell lines. β-Actin was used to demonstrate overall protein level normalization.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 5.
Response of Head and Neck Squamous Cell Carcinoma (SCC) Cell Lines to ERBB2 Inhibitors

A-D, A subset of University of Michigan (UM)-SCC cell lines demonstrated sensitivity to ERBB2 tyrosine kinase inhibitors. In our panel of cell lines, UM-SCC-1, UM-SCC-110, and, to a lesser extent, UM-SCC-23 demonstrated sensitivity to ERBB2 inhibitors currently in clinical trials. CP724714 (C) is a ERBB2-specific inhibitor; the remaining inhibitors have some combination inhibition of EGFR as well. UM-SCC-1 showed significantly higher ERBB2 expression and appeared to be the most responsive of the UM-SCC cell lines.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

265 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();